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Background: ClinicalTrials.gov is the primary registry for federally and privately funded 
clinical trials conducted in the United States. Unlike the more commonly used parallel 
design, in which each participant is randomized to a certain treatment, in a crossover design, 
each participant is randomized to a sequence of treatments and each participant serves as 
his/her own control in estimating treatment effect. This distinct feature makes the design and 
registration of crossover trials different from that of parallel trials. 
 
Objective: To characterize Phase 3 crossover trials registered on ClinicalTrials.gov; to 
identify registration issues using current system; to inform the development of practical 
guidance to improve registration of crossover trials on ClinicalTrials.gov. 
 
Method: We searched ClinicalTrials.gov on Sep 15, 2014 for trials labeled ‘Crossover 
Assignment’ in the intervention model, randomized, phase 3, and having results registered 
and citation provided. Two reviewers independently assessed the eligibility and extracted 
data on study design details, reporting groups, primary outcomes and adverse events to an 
electronic form developed on Systematic Review Data Repository. We tabulated the numbers 
of trials with specified characteristics and described issues in the definitions, instructions, and 
in using the registration template. 
 
Results: Registration of crossover trials was mixed. Only three quarters of included Phase 3 
studies (75%, 54/72) labeled as ‘’Crossover Assignment’ trials were real randomized, 
crossover trials. We found variations of registration format for different sections. Majority of 
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the trials (81.5%, 44/54) presented the outcome following a parallel instead of crossover 
structure. We proposed guidance for table creation with examples for registering 
arms/interventions, participant flow, baseline characteristics, outcome and adverse events 
respectively, to help improve the registration of crossover trials on ClinicalTrials.gov. 
 
Conclusion: Many of studies labeled as ‘Phase 3 Crossover Assignment’ have problems in 
registration on ClinicalTrials.gov The proposed strategy has the potential to improve 
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Chapter 1: Background 
1.1 ClinicalTrials.gov 
ClinicalTrials.gov is a publicly available and web-based clinical trials registry, maintained by 
the National Library of Medicine of the National Institutes of Health (NIH). It has become 
the primary registry for federally and privately funded clinical trials conducted in the United 
States. Registration at ClinicalTrials.gov began in 2000. Since 2007, the US Food and Drug 
Administration Amendments Act required trials that are subject to FDA regulation or funded 
by NIH to report basic results in the ClinicalTrials.gov database, including data elements 
related to participants demographics, baseline characteristics, outcomes and statistical 
analyses, as well as adverse events. 1 
 
1.2 Crossover design 
Trials registered on ClinicalTrials.gov can utilize different designs. Unlike the more 
commonly used parallel randomized controlled trial where each participant is randomized to 
receive one of the treatments (for example, treatment A or treatment B), in a crossover trial, 
participants are assigned to a sequence of treatments (treatment A then treatment B or vice 
versa) and treatment effect is estimated based on within-individual difference as each subject 
serves as his/her own control 2 (Figure 1). The major advantage of using a crossover design is 
that, by removing the between-subject variations, in most cases, a sample size is needed to 
detect individual treatment differences compared to a parallel design. 3 
 
However, using repeated measurements of same subjects from multiple intervention periods 
brings in potential disadvantages, which needs special attention in design and analysis. The 
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first problem is the missing data issue, especially resulting from dropouts. 3 Although missing 
data due to dropout may challenge the analysis and interpretation for both parallel and 
crossover design trials, it is more of a concern for crossover trial compared to parallel one. If 
one subject dropped out after the first intervention in a parallel trial, data collected up to 
discontinuation may still contribute to analysis of treatment effect up to the time point of 
discontinuation; yet, in a crossover tria l, data collected from the first period would be wasted 
if there were missing data from the subsequent periods because a within-individual 
comparison is not possible. Therefore, participant flow including missing data, and time 
frame for measured values are of vital importance for registering crossover trials.  
 
The second issue is the risk of carryover effect, that is, there may be a persistent or residual 
effect from treatment in one period on the subsequent period of treatment, such that the 
comparative treatment effects may be confounded. For example, if the effect of treatment A 
from period 1 persists to period 2, when a subject is receiving treatment B, the simultaneous 
treatment effects from both A and B will be observed in the second period; yet, only B’s 
effect is considered, leading to invalid interpretation of comparative treatment effects. 
Another issue is the period effect, where differential secular changes may exist such that the 
treatment effects are not consistent over time, resulting in treatment by period interaction.  
 
Because of these important distinctions between parallel and crossover designs, and issues 
specific to crossover design, the registration of the design, analysis, and results of crossover 
trials is different from that of parallel trials. 2 These design and analysis features need to be 




A recent study by Li et al. (2014) 4 evaluated the characteristics of a large number of 
crossover trials in glaucoma literature. They found that the design and reporting were largely 
inadequate and analysis inappropriate, hence limiting their value to clinicians and patients. 
Nearly three quarters of glaucoma crossover trials were found to present outcome data as if 
the trial had a parallel design and ignored the paired-nature of data. 5 Because they only 
focused on published literature and because ClinicalTrials.gov database has a great potential 
to provide evidence for clinicians, patients and researchers, we would like to examine the 
registration of crossover trials on ClinicalTrials.gov and provide suggestions to improve the 
registration.  
 
1.3 Definitions from ClinicalTrials.gov registry for crossover design trials 
Registry websites generally provide ‘Glossary’ sections for explaining terms used, and 
ClinicalTrials.gov did so without exception. However, we found two versions of definitions 
for ‘crossover’ on ‘Glossary of Common Site Term’ (referred to as ‘Glossary’ document in 
the later paragraphs) 6 webpage and ‘Protocol Data Element Definitions (DRAFT)’ (referred 
to as ‘Protocol’ document in the later paragraphs) 7  page, the latter one was prepared 
especially for study record managers for guiding registration of trial information on 
ClinicalTrials.gov.  
 





“Describes a clinical trial in which groups of participants receive two or more 
interventions in a particular order. For example, a two-by-two crossover design 
involves two groups of participants. One group receives drug A during the initial 
phase of the trial, followed by drug B during a later phase. The other group receives 
drug B during the initial phase, followed by drug A during a later phase. So during 
the study, participants "cross over" to the other drug. All participants receive drug A 
and drug B at some point during the study, but in a different order, depending on the 
group to which they are assigned. One type of Intervention Model (Design).” 
 
In the ClinicalTrials.gov Protocol Data Element Definitions (DRAFT) (‘Protocol’ document) 
7, the term ‘Cross-over’ assignment was defined in the ‘Intervention Model’ section as:  
“Cross-over: participants receive one of two alternative interventions during the initial phase 
of the study and receive the other intervention during the second phase of the study”. 
 
The definition for ‘cross-over’ in the ‘Protocol’ document, although clear to some, may lead 
to a misunderstanding of what could be categorized as a randomized crossover trial and 
subsequently create registration errors on ClinicalTrials.gov. For example, some trials that 
have an observational phase in which all participants on the placebo arm receive the active 
intervention after the randomized phase would appear to meet the definition of ‘cross-over’ 
provided in the ‘Protocol data elements definitions’ document.  
 
ClinicalTrials.gov also provided a registration example for a crossover design study with a 
two-way AB|BA crossover design from a fictional manuscript 8 and results documents 9, to 
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give registrars a template for registering crossover studies on ClinicalTrials.gov. Even with 
the definitions in ‘Glossary’ 6, ‘Protocol’ 7 data elements documents and the sample example 
8, 9 for presenting crossover features, it is still not clear how to register appropriately using the 
table-format reporting structure on ClinicalTrials.gov.  
 
1.4 Exploration of other registries 
An exploratory search of 15 primary clinical trials registries listed on the WHO International 
Clinical Trials Registry Platform 10 in December 2014, showed that only a few registries 
provided definitions or glossary entries for a crossover design. 
Australia and New Zealand Clinical Trials Registry (ANZCTR) defined crossover 
assignment in the data field explanation document as: ‘Crossover: All participants receive all 
the interventions in different sequences during the study. They act as their own control.’11  
 
 The EU Clinical Trials Register (EU-CTR) glossary had a definition for the term ‘Cross 
over’ as ‘Comparison of two (or more) treatments in which patients switched to the 
alternative treatment after a specified period of time’. 12  
  
The German Clinical Trials Register (DRKS) defined ‘Crossover Assignment’ as ‘There are 
several groups (at least two), which receive every or at least several treatments in different 
sequences’. 13 
 
In summary, no uniform definition exists among these network registries. Discrepant 






Chapter 2: Methods 
2.1 Specific aims 
Aim 1:  To review and characterize the registration of design, analysis and results of phase 3 
crossover trials on ClinicalTrials.gov;  
Aim 2: To identify issues in registration using current format;  
Aim 3: To inform the development of practical guidance to improve registration of crossover 
trials on ClinicalTrials.gov. 
 
2.2 Selection of studies 
Studies registered on Clinicaltrials.gov meeting the following criteria will be eligible for 
inclusion. 
Eligibility criteria:  
 Trials labeled as ‘Crossover Assignment’ in the intervention model 
 Randomized trials 
 Phase 3 (study phase) trials 
 Trials with results registered by the search date (September 15, 2014) 
 Trials with citations/publications linked to ClinicalTrials.gov 
 Trials with at least one primary outcome registered on ClinicalTrials.gov by the 
search date (September 15, 2014).    
 
2.3 Search strategy 
A colleague from ClinicalTrials.gov searched ClinicalTrials.gov on September 15, 2014, 
using the registry’s ‘Advanced Search’ function with the following key terms: ‘Crossover 
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Assignment’ (in ‘Intervention Model’), any text (not blank) in the ‘Results First Received 
Date’ and ‘Citation’ section and sent us 367 studies (see Appendix 1 for search strategy). For 
the search results, we selected studies labeled as ‘Phase 3’ and ‘Allocation’ as ‘Randomized’ 
for this project. Two individuals working independently manually evaluated each registration 
identified from the search against the eligibility criteria. In the case when the 
ClinicalTrials.gov registry provides insufficient information to determine if the trial was a 
randomized crossover trial, we referred to citations provided by trial sponsors or 
investigators, indexed in the ‘Publications’ section on ClinicalTrials.gov. If more than one 
publication were listed, we manually checked all publications. If no indexed publication 
provided the information we need, we manually searched PubMed using the trial’s NCT 
number or the conditions, interventions, investigators information registered on 
ClinicalTrials.gov. We resolved data abstraction discrepancies through adjudication or 
consultation with a third person on the team. 
 
Data extraction 
For those registrations that met our eligibility criteria, using the ‘Download’ search results 
function, we exported the following data elements from data fields available from 
ClinicalTrials.gov:  
- Study identification, including ‘Organization’s Unique Protocol ID’, ‘Official Title’ and 
‘Study Type’;  
- Study status, including ‘Overall Recruitment Status’, ‘Primary Completion Date’;  
- ‘Sponsor’ and ‘Responsible Party’ (investigator’s information);  
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- Oversight information, including ‘FDA Regulated Intervention?’ (Indicator of whether 
the trial includes an intervention subject to FDA regulation);  
- Study description, including ‘Brief Summary’ and ‘Detailed Description’; ‘Conditions’;  
- Study design, including ‘Primary Purpose’, ‘Study Phase’, ‘Intervention Model’, 
‘Number of Arms’,’ Masking’, ‘Allocation’, ‘Study Classification’, and ‘Enrollment’; 
- Arms information, including ‘Arm Label’, ‘Arm Type’ and ‘Arm Description’ 
- ‘Participant Flow’ section, including ‘Recruitment Details’, ’Pre-assignment Details’, 
‘Arm Title’, ‘Arm Description’ and ‘Period Title’;  
- ‘Baseline Characteristics’ section, including ‘Arm Title’, ‘Arm Description’, ‘Overall 
Number of Baseline Participants’, ‘Baseline Analysis Population Description’, ‘Baseline 
Measure Title’, ‘Measure Type’, ‘Measure Dispersion’, ‘Category Title’ and ‘Baseline 
Measure Data’;    
- Outcome Measures section, including ‘Outcome Measure Type’, ‘Outcome Measure 
Title’, ‘Outcome Measure Description’, ‘Outcome Measure Time Frame’, ‘Outcome 
Measure Safety Issue’, ‘Arm Title’, ‘Arm Description’, ‘Number of Participants 
Analyzed’, ‘Type of Units Analyzed’, ‘Analysis Population Description’, ‘Measure 
Type’, ‘Measure of Dispersion/Precision’, ‘Category Title’, ‘Statistical Analysis 
Overview’, ‘Statistical Test’, ‘Method of Estimation’ and ‘Estimation Comments’; 
- ‘Serious Adverse Events’ and ‘Other Adverse Events’ section, including ‘Arm Title’ and 
‘Arm Description’;        




In addition to the data fields that we exported directly from ClinicalTrials.gov, two 
individuals independently extracted the following information from a manual review of the 
registration: 
 
1)  ‘Arms’ and ‘Assigned Interventions’ 
‘Arms’ section on ‘Full Text View’ page provides the name for identifying the arms, and 
brief description for each arm to distinguish it from other arms in the trial. ‘Assigned 
Interventions’ specifies the interventions used for that arm, next to the ‘Arms’ 
information in a table format. A key feature differentiating crossover trial from parallel 
one is that, participants are randomized to a sequence of interventions, instead of certain 
intervention(s), and thus, the specified arms in a crossover trial should represent the 
randomized sequences in each trial (registered ‘By sequence’), instead of one 
intervention for one arm in a parallel trial (usually registered ‘By intervention’). It is 
important to identify how registrars presented arms and interventions for crossover trials. 
We abstracted the method of registration of the trial arms and study interventions in the 
current table format in the registration system, and summarized the variation of 
registration: ‘By sequence’, ‘By intervention’, ‘By period’ or ‘Others’ (see example 15 in 
Appendix 3). We proposed an appropriate and consistent approach for registering ‘Arms’ 
and ‘Assigned Interventions’.  
 
2) Classification of study design 
By reviewing the trial description, arms description and treatment assignments, we then 
identified the number of compared interventions used in the trial, the number of treatment 
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periods and the number of sequences registered, and summarized the study design. For 
example, a simple crossover design comparing two treatments, with two periods and 
therefore two sequences was expressed as ‘AB|BA’ design.  We summarized the different 
crossover designs of all included trials.  
 
3) ‘Reporting Groups’ 
Reporting Groups’ is used by the ClinicalTrials.gov template to create the column names 
in each section. When registering results in ClinicalTrials.gov, trial sponsors or 
investigators would specify the Reporting Groups for ‘Participant Flow’, ‘Baseline 
Characteristics’, ‘Outcome measures’ and ‘Adverse Events’ sections respectively. For 
example, if a registration specified that the ‘Reporting Groups’ in ‘Participant Flow’ 
section is by sequence (see example 22 in Appendix 3), the column names for 
‘Participant Flow’ table would be labeled according to the different sequences. The 
similar structure applies to ‘Reporting Groups’ in different sections of the registration, 
which can be created differently from other sections. We recorded how the ‘Reporting 
Groups’ for each section were registered. We summarized the variations for registering 
‘Reporting Groups’ and provided appropriate examples for each section.  
 
4) ‘Participant Flow’ 
The progress of research participants through each stage of the trial is documented in a 
tabular format on ClinicalTrials.gov, which may be separated into several ‘periods’, with 
each period presented by a separate table. We recorded how participant flow information 
was reported in the table format on ClinicalTrials.gov, including whether tables were 
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presented by period, intervention, etc. (see example 23 in Appendix 3), and whether the 
run-in or washout periods were presented or explained. We summarized the variations in 
table presentation and addressed the appropriateness of different ways for presenting 
participant flow for a crossover trial. 
 
5) ‘Outcome Measures’ 
Trial outcome data are also presented in a tabular format on ClinicalTrials.gov. 
Descriptive information is registered for outcome titles, description and time frame. 
Numeric data and description of statistical analyses are registered for outcomes. We 
included studies with results of at least one primary outcome available, and for the 
purpose of this study, we abstracted data from the first registered primary outcome if 
there is more than one primary outcome registered. We summarized the ‘specific metric’, 
‘method of aggregation’, specified ‘time frame’ for each outcome type (continuous 
outcome, categorical outcome, and time-to-event outcome) following the framework 
proposed by Zarin, et al (2011) 14, as well as the registering of the analysis population, 
methods of statistical analyses and associated issues. 
 
2.4 Data management 
We have provided a paper version of our online form in Appendix 2. We used Systematic 
Review Data Repository (SRDR) for data collected and management 15. Data were collected 
and coded on SRDR with unique NCT 16 identifiers linked to each trial. After data extraction 




2.5 Statistical analysis 
We tabulated the distribution of each characteristic of the included trials using STATA 13®. 
We described issues in the definitions, instructions, and in using the registration template, 




Chapter 3: Results 
3.1 Eligible studies 
Using our search strategy (Appendix 1) through ClinicalTrials.gov search query on 
September 15, 2014, we identified a total of 367 ‘Crossover Assignment’ studies with 
‘results’ and ‘citations’ reported on ClinicalTrials.gov (Figure 2). We excluded 9 trials with 
allocation labeled as ‘Non-randomized’, 286 trials with study phases other ‘Phase 3, and 18 
trials that we judged as not randomized crossover trials, respectively (Figure 2). We included 
54 studies in our subsequent data abstraction (Figure 2). 
 
3.2 Characteristics of included phase 3 randomized crossover trials  
Crossover-design trials registered on clinicaltrials.gov tested interventions for a variety of 
conditions, ranging from asthma, pain, and migraine to prostate cancer and chronic kidney 
disease (stage 5), etc. Table 1 summarizes the registration characteristics of 54 phase 3 
randomized crossover trials. Trial characteristics in Table 1 are provided and listed in 
‘Protocol’ document, except for the last item ‘Crossover design sequence’, which was 
summarized by reviewers for certain crossover design. The majority of trials (77.8%, 42/54) 
were registered using ‘double blind’. Among those 42 trials that registered ‘double blind’, 
almost all trials (97.6%, 41/42) had ‘Subject’ masked, 42.9% (18/42) had ‘Caregiver’ 
masked,  and 95.2% (40/42) for ‘Investigator’ and 42.9% (18/42) for ‘Outcome Assessor’ 
respectively.  
 
Based on the information provided in ‘Purpose’ and/or trial ‘Detailed Description’ sections 
on ‘Full Text View’ page on ClinicalTrials.gov, we identified that nearly two thirds (64.8%, 
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35/54) of the included trials used a simple ‘AB|BA’ crossover design and 20.4% (11/54) of 
the trials used a balanced and complete block of six sequences design 
‘ABC|ACB|BCA|BAC|CAB|CBA’. The remaining 7.4% (8/54) trials used designs with 
repeated treatment periods, such as ‘ABA|BAB’ (NCT00131248) 17 and ‘AAB|ABA|BAA’ 
(NCT00812006) 18; incomplete block designs such as ‘ABC|BAC|CAB’ (NCT00999908) 19, 
or others. Two studies used more than 6 sequences in the crossover design: 12 sequences in 
trial NCT00615030 20 with a total sample size of 96 participants, and 18 sequences in trial 
NCT01072149 21 with a total sample size of 54 participants.       
 
3.3 Registration of ‘Arms’ and ‘Assigned Interventions’ section    
In order to explore the variations in registering crossover trials, we provided examples of 
how arms and interventions are currently registered in Appendix 4. For 47 trials using a 
complete block design, where participants received all interventions in a trial through 
different periods, 27 trials presented the same information in the ‘Assigned Interventions’ 
cells for all rows, as all interventions were checked in the ‘Cross-Reference’ table for each 
arm in the registration system. We found a variety of registration formats for ‘Assigned 
interventions’ and ‘Arms’ in the included studies, with nearly one third (31.5%, 17/54) 
registered the ‘Reporting Groups’ in ‘Arms’ section ‘by Intervention’, similar to a parallel 
design trial, and nearly two thirds (63.0%, 34/54) registered by Sequence. The reviewers 
were unable to categorize the registration of ‘Assigned interventions’ and ‘Arms’ for 5.6% 




We present below three examples of poor registration of arms/interventions. Trial 
NCT00894556 22 registered three sequences in the first three rows of the ‘Arms’ section, and 
included an additional arm labeled as ‘Baseline Phase’ (Figure 3), which would be confusing 
to be included as an arm of the trial. ‘Arms’ section for this crossover trial should be used to 
specify compared sequences and information from the first three rows in the figure would be 
sufficient.  
 
Trial NCT00200967 23 recruited two genotype subpopulations in the trial with the objective 
to compare the treatments effects between two populations. Each genetic subpopulation was 
registered as one arm of the trial and two-sequence crossover within each genetic 
subpopulation was specified in ‘Arms description’ under each subpopulation (Figure 4). The 
presentation and explanation was not clear enough to clarify the exact comparison arms of 
the trial, either two subpopulations or two crossover sequences within each subpopulations.     
 
Trial NCT00395304 24, with a complete block three-treatment, three-periods, six sequences 
crossover design, registered all crossover sequences in one ‘Arm’ cell in the registration 
system (Figure 5). Every arm in this trial received the exact same interventions but in 
different orders. The arms/interventions table is designed for specifying one arm in one row 
in the registration system. We suggest that the six arms should be specified in six different 
cells in the registration system instead of piling in the same cell, and using the ‘cross-
reference’ function in the system to specify the assigned interventions for each arm 
accordingly, resulting in six rows in the arms/interventions section, each row representing 




3.4 Registration of ‘Participant Flow’ section 
Majority of included trials (92.6%, 50/54) registered ‘Arms/Groups Title’ by Sequence, 5.6% 
(3/54) by Intervention, and 1.9% (1/54) registered in a way that could not be categorized by 
the reviewers. Trial NCT00364182 25 registered the ‘Reporting Groups’ in ‘Participant Flow’ 
section both by Sequence and by Period (Figure 6), separating the pre-randomization and 
post-randomization participant flow information in different reporting groups rather than 
presenting periods in the subsequent tables. 
 
In terms of presenting the ‘Participant Flow’ tables, most of the trials (85.2%, 46/54) 
presented separate tables by period, but still, 14.8% (8/54) of trials provided only one table 
for the ‘overall/total study population’, which essentially failed to provide information about 
participant flow through several periods in the trial. Twenty-four (44.4%, 24/54) trials 
presented the flow through non-treatment periods in addition to treatment periods, including 
tables for pre-randomization and/or washout periods (Table 2). Less than half of included 
trials (37.0%, 20/54) clearly stated or showed that a washout period was included in the 
‘Purpose’ and ‘Detailed Description’ of the Arms/Intervention section, in the ‘Participant 
Flow’ section, or in text descriptions.    
 
We observed a few exceptions in how the ‘Participant Flow’ was registered. Trial 
NCT00894556 26 (Figure 7) used participant flow tables to present two study periods: one 
pre-randomization phase (labeled as ‘Baseline Phase’) and one post-randomization phase 
(labeled as ‘Treatment Phase’) without showing flow within the treatment phase through 
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crossover periods. Trial NCT00565266  27 (Figure 8) created one reporting group for the 
entire study, without separating the flow of participants assigned to different sequences 
through different periods.  
 
3.5 Registration of ‘Baseline Characteristics’ 
Of the 54 included trials, almost all trials (96.3%, 52/54) presented characteristics for the 
entire study population. Additionally, we found 38.9% (21/54) of trials presented baseline 
characteristics by sequence, and 5.6% (3/54) presented by period. For those including the 
‘Total’ group, we observed variations in terms used to describe the group, such as ‘Overall 
Study Population’, ‘Entire Study Population’, ‘All participants’, ‘Safety Population’ (i.e.: 
defined as ‘Participants who were randomized and who treated at least one migraine attack 
with investigational product in trial NCT00382993 28).  
 
3.6 Registration of ‘Outcome Measures’ 
The number of primary outcomes registered ranged from one to eight. Majority of trials 
(88.89%, 48/54) registered one primary outcome. Trial NCT00837967 29 and trial 
NCT00666263 30 registered 6 and 8 primary outcomes respectively.  
 
In terms of outcome type, 74.1% (40/54), 9.3% (5/54), 3.7% (2/54) registered the first 
primary outcome as continuous, categorical and time-to-event outcomes respectively. In 
13.0% (7/54) of the registered trials, we could not categorize the outcome type based on the 
provided information. Table 3 shows the summary statistics for specific metric and method 
of aggregation for the 1st primary outcome. Explanation for the ‘Time Frame’ information 
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was mixed. We found more than one third (38.9%, 21/54) of trials did not clearly explain the 
‘Time Frame’ for the outcome, only defining the time frame for the measurement duration 
(i.e.: outcome was measured after 2-4 hours of administration), without providing sufficient 
information on whether data are collected during all periods or a subset of periods (i.e.: 
unclear about whether outcome was measured after 2-4 hours of administration from period 1 
and period 2, or from 1st period only).  
 
For ‘Reporting Groups’ in the primary outcomes section (description of primary outcomes), 
most of trials (81.5%, 44/54) registered by Intervention, similar to that in the parallel trials, 
and only a few (9.3%, 5/54) registered by Sequence. One trial (1.8%, 1/54) presented the by 
Total only, 1 (1.8%, 1/54) trials by Period, and 5.6% (3.54) in other ways (i.e., grouped by 
subpopulation in trial NCT00200967 29; one group only instead of presenting compared arms, 
(i.e.: titled as ‘Ciclesonide Versus Mometasone’ in trial NCT01401465 31 and titled as 
‘Tapentadol’ in trial NCT00594516 32, Figure 9). 
 
Description of ‘Analysis Population’ plays an important role in understanding how outcome 
data is collected and analysis in a certain trial. Yet, we found 16.6% (7/54) of trials were 
missing in describing ‘Analysis Population’ for primary outcome. Of those 83.4% explaining 
the analysis population in the ‘Population Description’ field, ‘Intention-To-Treat (ITT)’ 
(29.6%, 16/54), ‘Per-Protocol (PP)’ (13.0%, 7/54), ‘modified Intention-To-Treat (mITT)’ 
(13.0%, 7/54) and ‘Full Analysis Set (FAS)’ (13.0%, 7/54) were frequently used by registrars 
and explained in their own ways for different trials. The remaining 14.8% (8/54) defined the 
analysis population using free text in the way without using above frequent terms, and 
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reviewers were unable to categorize as one of the term above. Similar to previous reports 
showing variations in defining analysis population in trials in published literature 33, 34, 
reviewers in this project observed many variations in the descriptions used by registrants for 
each type of analysis population, especially when free text was used for input. Some 
examples of the descriptions for ITT were shown below, and the variations in descriptions 
for FAS, PP and mITT were much greater.  
 
 “ITT. Although only 157 participants completed all three treatment periods, there 
was sufficient data on 8 additional participants to include them in the analysis of the 
primary outcome.” (Trial NCT00395304 35) 
 “Intention-to-treat (ITT) population: all enrolled participants” (Trial 00364182 36) 
 “ITT (Intent-to-Treat) Population - included subjects in the Safety Population who 
provided an evaluation of their study drug for at least one treated attack.” (Trial 
00382993 28) 
 
In assessing how period-specific values were presented in the table format on 
ClinicalTrials.gov, we found only 5.5% (3/54) of trials specified measured values with 
correspondent periods, and 94.4% (51/54) of trials failed to provide period specific measured 
value and presented one measure value only for each reporting group. Although all studies 
had at least one measured values of the primary outcome(s) registered, less than sixty percent 
(59.3%, 32/54) of the trials provide descriptions of the statistical analysis on 





3.7 Registration of ‘Adverse Events’ 
All the included trials had ‘Serious Adverse Events’ and/or ‘Other Adverse Events’ (Table 2) 
registered, and majority of them (87.0%, 47/54) registered by Intervention as were in parallel 
trials. Only 7.4% (4/54) of trials registered by Sequence and 7.4% (4/54) teased out the 
counts of adverse events by Period. We found three trials (NCT00364182 36, NCT00518531 
37, and NCT00904670 38) registered both by intervention and by period, and one trial 
(NCT00494143 39) registered both by sequence and by intervention. We were unable to 





Chapter 4: Discussion 
To our knowledge, this study is the first study to characterize and evaluate registration and 
reporting of randomized, crossover-design trials on ClinicalTrials.gov. We selected Phase 3 
trials only for this review, since they are more likely to have results published in full in the 
scientific literature 41. The methods used in this study can be applied to evaluate crossover 
trials from all other phases and the problems identified with registration are likely similar for 
early phase trials.  
 
The ideal strategy for improving registration is to suggest minimal changes that can be 
adapted to the current structure on ClinicalTrials.gov registry. Our review focused on 
evaluating whether the registration of the design, analysis, and results of randomized 
crossover trials in clinicaltrials.gov under the current format in the registry system properly 
captures the crossover design features. We then provided recommendations for registering 
‘Arms/Assigned Interventions’, ‘Participant Flow’, ‘Baseline Characteristics’, and two for 
continuous and binary primary outcomes for ‘Outcome Measures’ respectively.   
 
4.1 Registration issues and implications  
 
4.1.1 Misclassification of ‘Crossover Assignment’ as ‘Intervention Model’ 
Our review showed that 25% of phase 3 trials labeled as ‘Crossover Assignment’ in the 
intervention model on ClinicalTrials.gov were not using a crossover design for allocating 
experimental interventions; instead, these trials were typically allowing intervention changes 
during the course of the trial which were not randomized. The differences in clarifying 
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‘crossover’ as an experimental design versus crossovers during observation, either per 
protocol or as protocol violation, need to be addressed. It has to be made clear to registrars 
that those allowing participants to ‘crossover’ to other interventions should not be 
categorized as ‘Crossover Assignment’. The term ‘crossover’ should be used as the specified 
intervention model if the goal is to compare treatment differences using within-subject 
measurements on different interventions. 
 
The definitions for ‘crossover’ provided in ‘ClinicalTrials.gov Protocol Data Element 
Definitions’ document 8 should be edited to clarify the use of the crossover as an 
experimental design feature to avoid further misclassifications of trials. The definition for 
‘Crossover Design’  in the ‘Glossary’7 on ClincialTrials.gov correctly states that the 
sequences for comparison of the arms should be randomized; yet, the objective of analysis 
and how data should be aggregated are missing from the definition. The feature of having 
participants receiving multiple sequences of treatments is not sufficient to make a trial a 
‘crossover’ trial. 3 The CONSORT statement has not been extended to cover the crossover 
design yet 45, and there are no guidelines available for appropriate registration and reporting 
of crossover design trials in publications or registries. A consistent definition for ‘Crossover 
Design’ is needed, so that further reporting instructions can be developed.   
 
4.1.2 Proposing a good way for registering in the table format on ClinicalTrials.gov 
We observed many variations among the naming of Arms/Interventions and ‘Reporting 




 Recommendation 1: Registering ‘Arms/Interventions’ section  
In a typical two-arm parallel design trial with two experimental interventions A & B, 
each registered arm corresponds to one intervention. The presentation of the 
Arms/Interventions table is straightforward and illustrated in Figure 10 (upper panel). An 
example of registering a AB|BA crossover design trial was presented in Figure 10 (lower 
panel). The arm in a crossover trial essentially refers to one sequence, and thus, registrars 
would choose all related interventions used in this particular sequence by checking 
interventions in the ‘cross-reference’ section in the ClinicalTrials.gov registration system. 
If the crossover design were balanced and complete, the assigned interventions cells 
would be exactly the same across all rows in the ‘Assigned Interventions’ column shown 
on ‘Full Text View’ page. 
 
For ‘Participant Flow’, ‘Baseline Characteristics’, ‘Outcome Measures’ and ‘Adverse Event’, 
registrars would need to specify the reporting groups separately for each section. The 
specified ‘Reporting Groups’ are then used to create the column groups for registering 
comparisons groups in each section.  
 
 Recommendation 2: Registering ‘Participant Flow’ 
In the ‘Participant Flow’ section, a reasonable way to report groups is by sequence and to 
present separate tables for randomized intervention periods. Other pre-randomized 
periods, open-label phases, run-in, run-out, and washout periods etc. can also be 
presented by adding more period-tables in addition to the intervention periods in the 
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participant flow section to illustrate flow. A proposed way of registering the ‘Participant 
Flow’ section is shown in Figure 11.  
 
 Recommendation 3: Registering ‘Baseline Characteristics’ 
For ‘Baseline Characteristics’, the comparison of interest is in the baseline characteristics 
by different assigned sequences. Therefore, registrars could report characteristics by 
sequence (Figure 12) in this section, in addition to registering a ‘Total’ column.  
 
 Recommendation 4: Registering ‘Outcome Measures’ for continuous and binary 
outcomes 
For ‘Outcome Measures’, the way reporting groups are created has to do with the trial 
objectives, the outcome types, and potentially the ways data were analyzed. We found it 
difficult to determine the outcome type, specific metric, time frame and method of 
aggregation from ‘Outcome Measures’ due to inadequate description of trial details on 
ClinicalTrials.gov. Built upon a previous study 4 with an example of registering 
continuous outcome for an AB|BA crossover trial, we propose a transformed table for 
registering continuous outcomes to fit into the current table format on ClinicalTrials.gov 
registration system (Figure 13). Figure 14 illustrates a registration format of binary 
outcome for an AB|BA crossover-design trial, where numbers from each period and each 
sequence, as well as the concordant and discordant counts are listed in the measured 




As participants in a crossover trial receive at least two or more interventions, the ideal 
presentation for adverse events is to present the analysis of adverse events by intervention 
and by periods. However, how the event counts are to present mainly depends on the 
rationale of study design, teasing out events resulting from different interventions, and 
the availability of collected data, by periods separately.  
 
 Recommendation 5: Registering statistical analyses 
More than 40% of trials were missing in the statistical analyses for the 1st primary 
outcome, and much fewer presented period-specific measured values. With inadequate 
information on measured values and statistical analyses, the summary data provided on 
ClinicalTrials.gov is of limited use to readers since it is difficult to interpret the meaning 
of the results. Currently, for non-inferiority or equivalence trials, it is ‘Conditionally 
required by ClinicalTrials.gov’ to identify whether the statistical analysis was testing 
non-inferiority or equivalence by checking in the registration system, and to include a 
definition of the non-inferiority margin and other key design parameters 8. We suggest 
that the paired-nature of data in the crossover design trial needs to be addressed when 
registering trial results on ClinicalTrials.gov. A similar checking question to non-
inferiority or equivalence trial could be used to identify crossover trial as well 
 
4.1.3 Registration of time-to-event data 
When it comes to time-to-event data, appropriate registration of outcome data becomes more 
challenging, especially for fitting in the table template provided by ClinicalTrials.gov. 
Among included studies, we found two trials registering the primary outcome as a time-to-
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event outcome, trial NCT00004635 42 (Figure 15) and trial NCT01808755 43. These two trials 
presented one median or mean of the primary outcome in ‘Outcome Measure’ section; yet, 
neither of the trials provided statistical analysis for the primary outcome. A potential strategy 
is to report the repeated measurement events at several time points (for example, the n(%) 
with event at time t, at time t+1, at time t+2, etc.), an idea used in trial NCT00500149 44, 
where registrars reported measured values at several time points (Figure 16). Further 
evaluation is needed to propose a proper way for registering time-to-event data on 
ClinicalTrials.gov.  
 
4.2 Proper use and registration of crossover designs 
Using a crossover design has several merits. The most important one is to remove factors 
attributable to between-subject differences that may affect intervention comparisons. By 
comparing treatment effects within each participant, a crossover trial could be more efficient 
(i.e., require a smaller sample size) than a parallel-design given the same assumptions for 
sample size 45. However, the potential disadvantages of using a crossover design include the 
potential carryover effect and period effect. Very few trials included in this project described 
clearly the rationale for using a crossover design or addressed the potential carryover effect.  
 
Losses to follow-up can be particularly serious for crossover designs. Each participant in a 
crossover-design trial contributes data for two or more periods, and data from multiple 
intervention periods is collected and aggregated to estimate the overall effect so all periods 
are potentially unusable when a participants is lost to follow-up. It is important to show the 
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There are several limitations with this study. First of all, we chose a sample of trials by 
examining phase 3 trials only as our first step for approaching registration issues related to 
crossover design trials on ClinicalTrials.gov registry. We expect that phase 1 and 2 trials 
have similar registration problems but cannot ensure that these results generalize to other 
phases.  
 
In evaluating ‘Outcome Measures’, we focused on the first listed primary outcome when 
more than one primary outcome was registered and reported. The majority (88.9%) of trials 
listed only one primary outcome but it is possible that the other primary outcomes that we did 
not review had different registration problems.  
 
Since there are currently no CONSORT guidelines on how crossover designs should be 
reported, 46 we did not compare the results posted on ClinicalTrials.gov to the results in the 
primary publication.  
 
A next step is to compare the information reported on ClinicalTrials.gov with publications 
for each trial to figure out the registration and reporting discrepancies, quality and identify 





It is important for ClinicalTrials.gov to understand the key issues related to crossover design 
trial and provide appropriate guidance for registrars to correctly register trial details on the 
registry. This research project is funded by a contract from ClinicalTrials.gov. By providing 
recommendations tailed to crossover trials and requiring minimal changes to the current 
database structure, the results from this project would be taken up by ClinicalTrials.gov soon.  
 
To our knowledge, the CONSORT group is currently working on gathering data on crossover 
trials to develop reporting guidelines for crossover trials. This research project comes out 
timely to provide some insights for them to take in. From this research, we realized the 
inadequate understanding of crossover design trial among trialists, resulting in misclassifying 
the intervention model and missing in presenting key features specific to crossover design on 
the trial registry. In the end, it’s the trialists’ responsibility to understand the design, use it 





Chapter 5: Conclusion  
In conclusion, many of trials registered on ClinicalTrials.gov, labeled as “Phase 3 Crossover 
Assignment”, have problems in registering the design, results and analysis of crossover 
design trials on the trial registry. Clear understanding of crossover trial and associated 
analytic and reporting issues, as well as good understanding for registration database 
structure plays the key roles for providing valid data on the trial registry. The addressed 
issues and proposed strategies have the potential to improve registration of the design and 
results of crossover trials on ClinicalTrials.gov, and provide insights for other groups to 





Table 1. Characteristics of phase 3 crossover trials registered on ClinicalTrials.gov 
searched by Sep.15 2014 (n = 54) 
Item Characteristics ₸     Number               (Percent) 
Study classification 
 
Efficacy Study 17 (31.5%) 
Safety/Efficacy Study 32 (59.3%) 
Safety 1 (1.9%) 
Pharmacodynamics 1 (1.9%) 
(Blank) 3 (5.6%) 
Funding source 
 
Industry 43 (79.6%) 
Other | Industry 1 (1.9%) 
Other 3 (5.6%) 
Other | NIH 4 (7.4%) 
Other | U.S. Fed 2 (4.0%) 
NIH | Other | U.S. Fed 1 (1.9%) 
Intervention type 
 
Drug 47 (87.0%) 
Biological 3 (5.6%) 
Device 3 (5.6%) 
Dietary Supplement | Drug 1 (1.9%) 
Masking 
 
Open Label 9 (16.7%) 
Single Blind  3 (5.6%) 
Double Blind 42 (77.8%) 
Masking parties for 
double blind trials 
 
Subject 41  
Caregiver 18  
Investigator 40  
Outcome Assessor 18  
 N/A 12  
Crossover sequence 
design 
AB|BA 35 (64.8%) 
ABC|ACB|BCA|BAC|CAB|CBA 11 (20.4%) 
AAB|ABA|BAA 2 (3.7%) 
ABC|BAC|CAB 1 (1.9%) 
ABA|BAB 1 (1.9%) 
Others 4 (7.4%) 
₸: The above trial characteristics, except for those listed in ‘Crossover sequence design’ section, are 








Table 2. Summary of Crossover Design features for ‘Arms’, ‘Assigned Interventions’, 
‘Participant Flow’, ‘Baseline Characteristics’ and ‘Adverse Events’ Sections 
Characteristics Number        (Percent)  
‘Arms’ section    
      By Sequence 34 (63.0%) 
      By Intervention 17 (31.5%) 
      By Period 0 (0%) 
      Cannot tell 3 (5.6%) 
‘Assigned Interventions’ section    
      Same treatment details for all rows 26 (48.1%) 
      Treatment details not the same for all rows 27 (50.0%) 
      Others 1 (1.9%) 
‘Reporting Groups’ in ‘Participant Flow’ section    
      By Sequence 50 (92.6%) 
      By Intervention 3 (5.6%) 
      By Period 1 (1.9%) 
      Others 1 (1.9%) § 
Presentation of ‘Participant Flow’ Tables   
      One table only for overall study/ total population 8 (14.8%) 
      Separate tables by Period, without  
      pre-randomization and/or washout periods 
22 (40.7%) 
      Separate tables by Period, with pre-randomization  
      and/or washout periods 
24 (44.4%) 
      Others 0 (0.0%) 
‘Reporting Groups’ in ‘Baseline Characteristics’ section   
      By Sequence 21 (38.9%) 
      By Intervention 0 (0.0%) 
      By Period 3 (5.6%) 
      By Total  52 (96.3%) 
      Others 6 (1.1%)  
‘Reporting Groups’ for ‘Adverse Events’    
      By Total  2 (3.7%) 
      By Sequence 4 (7.4%) 
      By Intervention 47 (87.0%) 
      By Period 4 (7.4%) 
      Others 1 (1.8%) 
§: One trial (NCT00200967)23 labeled the ‘Reporting Groups’ in ‘Participant Flow’ section ‘by 







Table 3. Summary of ‘Outcome Measures’ section 
Characteristics Number (Percent)   
Number of primary outcome registered    
      1 48 (88.89%) 
      2 2 (3.7%) 
      3 2 (3.7%) 
      > 3 2 (3.7%) 
Types of the 1st primary outcome ₸   
      Continuous outcome 40 (74.1%) 
      Categorical outcome 5 (9.3%) 
      Time-to-event outcome 2§ (3.7%) 
      Cannot tell 7 (13.0%) 
Specific metric for the 1st primary outcome    
      Value at a time-point 32 (59.3%) 
      Time-to-event 2  (3.7%) 
      Change from the baseline before randomization 1 (1.9%) 
      Change from the period-baseline 6 (11.1%) 
      Within-individual difference between values at the     
      end of each period 
3 (5.6%) 
      Within-individual difference between changes from baseline 1 (1.9%) 
      Others 3 (5.6%) 
      Cannot tell 6 (11.1%) 
Method of aggregation for the 1st primary outcome ₸   
      Number 11 (20.4%) 
      Mean 19 (35.2%) 
      Median 3 (5.6%) 
      Least squares mean 19 (35.2%) 
      Proportion / percent 2 (3.7%) 
‘Time Frame’ for 1st primary outcome includes all randomized periods  
      Yes 33 (61.1%) 
      Cannot tell 21 (38.9%) 
‘Analysis Population’ for the 1st primary outcome    
      ITT (intention-to-treat) 16 (29.6%) 
      PP (per-protocol) 7 (13.0%) 
      mITT (modified intention-to-treat) 7 (13.0%) 
      FAS (full analysis set) 7 (13.0%) 
      Not reported 9 (16.6%) 




Table 3. Summary of ‘Outcome Measures’ section (continued) 
‘Reporting Groups’ for primary outcome(s)    
      By Sequence 5 (9.3%) 
      By Intervention 44 (81.5%) 
      By Period 1 (1.8%) 
      By Total  1 (1.8%) 
      Others 3 (5.6%) 
‘Measured Values’ presented by Period   
      Yes  3 (5.5%) 
      No 51 (94.4%) 
Provides ‘Statistical Analysis’ for the 1st primary 
outcome 
  
      Yes  32 (59.3%) 
      No 22 (40.7%) 
Statistical methods for analyzing 1st primary outcome ₸           ( n = 32) 
      ANCOVA 3 (9.4%) 
      ANOVA 11 (34.4%) 
      Cochran-Mantel-Haenszel  1 (3.1%) 
      Generalized Estimating Equations 2 (6.2%) 
      Generalized Linear Mixed Model 2 (6.2%) 
      Linear mixed effects model 1 (3.1%) 
      Mixed Models Analysis 3 (9.4%) 
      Mixed effects ANOVA crossover model 1 (3.1%) 
      Non-Inferiority/Equivalence Test 2 (6.2%) 
      Prescotts Test 1 (3.1%) 
      t-test 1 (3.1%) 
      Two-sided Signed Rank Test 1 (3.1%) 
      Wilcoxon (Mann-Whitney)  2¶ (3.1%) 
      Wilcoxon signed rank 1 (3.1%) 
₸: The characteristics options in this item are provided in ‘Protocol’ and/or ‘Basic Results’ documents 
by ClinicalTrials.gov for guiding registration. Otherwise, other characteristics are summarized by 
reviewers. 
¶: Trial NCT01132118 reported two different statistical analysis method: ‘Wilcoxon (Mann-
Whitney)’ and ‘Regression, Linear’ for the first primary outcome.48  
























Crossover trials identified by the search strategy 
n = 367 
 Searched on Sep 15, 2014 
Trials excluded (n = 295):  
- Non-randomized   n = 9 
- Randomized 
     Phase 1   n = 59 
     Phase 1 | Phase 2  n = 11 
     Phase 2   n = 93 
     Phase 2 | Phase 3  n = 7 
     Phase 4    n = 54 
     Blank   n = 62 
Phase 3 ‘Crossover Assignment’ trials for screening 
n = 72 
Not randomized crossover trials (n = 18)  
- ‘Crossover’ not randomized    n = 17 
- Crossover not in phase 3     n = 1 
Phase 3 randomized crossover trials for data extraction 






Figure 3. Registration of arms/interventions in trial NCT00894556 
Note: This trial includes a ‘Baseline Phase: Sumatriptan’ as an arm, which we would suggest excluding it from the 
‘Arms/Interventions’ section. ‘Arms’ should be used to specify sequences to be compared in a trial. In this case, information 







     
Figure 4. Registration of arms/interventions in trial NCT00200967 
Note: The objective of this trial is to compare treatment effects between two populations of different genotypes. The 
crossover-design is set within each population. The two arms are used for registering the two populations. The 
presentation and explanation was not clear enough to clarify the exact comparison arms of the trial, either two 







Figure 5. Registration of arms/interventions in trial NCT00395304  
Note: This trial uses a complete block, three-treatment, three-period crossover design. Every arm received the exact 
same interventions but in different orders. We suggest that the six arms should be specified in six different cells in the 
registration system instead of piling in the same cell, and using the ‘cross-reference’ function in the system to specify 
the assigned interventions for each arm accordingly, which would result in six rows in the arms/interventions section, 






Figure 6. ‘Reporting Groups’ in ‘Participant Flow’ section in trial NCT00364182 
Note: The ‘Participant Flow’ section is designed to show how participants progress through the phases of a trial. The 
time components need to be specified in the title of the ‘Participant Flow’ section. We suggest that the ‘Pre-
Randomization’ row should be removed from ‘Reporting Groups’ and use the period specification function in the title 














Figure 7. Registration of ‘Participant Flow’ in trial NCT00894556 (continued) 
Note: It is helpful to show participant flow after administering ‘Sumatriptan’ in the ‘Baseline Phase’ period in the table. 
However, the flow through the three periods in the treatment phase is not specified. We suggest that a reasonable 
presentation would be to provide participant flow through each period by providing two more tables, and label the title for 







Figure 8. Registration of ‘Participant Flow’ in trial NCT00565266 
Note: In this table, the readers cannot tell during which period the participants were lost to follow-up. We suggest that a 
reasonable registration strategy would be to separate six reporting groups by assigned sequences and present at least three 






   
  
Figure 9. ‘Reporting Groups’ for 1st primary outcome in trial NCT00594516 
Note: The goal of this trial was to compare different formulations of the same-ingredient (Tapentadol IR formulation versus 
Tapentadol ER formulation). Instead of grouped in one ‘Tapentadol’, we suggest that registering the original aggregated 




Figure 10. Comparison of registration for arms/interventions in parallel-design and 
crossover-design trial 
 
- For parallel-design trial  
Arms Assigned Interventions 
Experimental: A  
(Description for A)  
Drug: A 
(Key details of Intervention A) 
Experimental: B 
(Description for B) 
Drug: B 
(Key details of Intervention B) 
 
- For crossover-design trial 
Arms Assigned Interventions 
Experimental: A first, then B  
(Description for sequence 1) 
Drug: A 
Drug: B 
Experimental: B first, then A 






Figure 11. Illustration of proposed way of registering ‘Participant Flow’ 
Reporting Groups 
 Description 
Sequence 1 -- A first then B … 
Sequence 2 -- B first then A …  
 
Participant Flow for 2 periods 
Period 1: Treatment Period I 
 Sequence 1 –  
A first then B 
Sequence 2 – 
B first then A 
STARTED N1 N2 
COMPLETED … … 
NOT COMPLETED … … 
 
Period 2: Treatment Period II 
 Sequence 1— 
A first then B 
Sequence 2 –  
B first then A 
STARTED N3 N4 
COMPLETED … … 





Figure 12. Illustration of proposed way of registering ‘Baseline Characteristics’ 
Reporting Groups 
 Description 
Total Population / Overall Study Population   
Sequence 1 -- A first then B … 
Sequence 2 -- B first then A …  
 
Baseline Measures 
 Total Population /  
Overall Study Population 
Sequence 1 –  
A first then B 
Sequence 2 –  















Figure 13. An illustrative example for registering continuous outcome for a two-
intervention two periods crossover design trial 
Reporting Groups 
 Description 
Sequence 1 -- A first then B … 
Sequence 2 -- B first then A …  
 
Measured Values 
 Sequence 1 – 
A first then B 
Sequence 2 – 
B first then A 
Number of Participants Analyzed 
[units: participants] 
N1 N2 
Outcome Measurement 1¶   
     Baseline Measurement§ … … 
     Value from Period 1 … … 
     Value from Period 2 … … 
     Within-individual difference♯ … … 
¶: ‘Outcome Measurement 1’ refers to ‘Measure Title’  
 §: (Optional). Whether it is need to specify ‘Baseline Measurement’ depends on the context and 
specific measurement of the trial. 
 ♯:’Within-individual difference’ can be changed based on how data were to analyze. 
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Figure 14. An illustrative example for registering binary outcome for a two-intervention 
two periods crossover design trial 
Reporting Groups 
 Description 
Sequence 1 -- A first then B … 
Sequence 2 -- B first then A …  
 
Measured Values 
 Sequence 1 – 
A first then B 
Sequence 2 – 
B first then A 
Number of Participants Analyzed 
[units: participants] 
N1 N2 
Outcome Measurement 1¶   
     Baseline Measurement § … … 
     (0, 0) ♯ … … 
     (0, 1) … … 
     (1, 0)    
     (1, 1) ♯ … … 
¶: ‘Outcome Measurement 1’ refers to ‘Measure Title’  
 §: (Optional). Whether it is needed to specify ‘Baseline Measurement’ depends on the context and 
specific measurement of the trial. 
 ♯: Optional for concordant counts. Whether it is needed to specify has to deal with how data is 



















Search syntax (367 studies were found on September 15, 2014) 
"Crossover Assignment" [DESIGN-INTERVENTION-MODEL] AND NOT NOTEXT 
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Appendix 2. Data Abstraction Form for Crossover Trials 
 
 
*1. Please enter the 11-character ClinicalTrials.gov registration number, beginning with NCT: 
N C T __ __ __ __ __ __ __ __ 
 
From questions 2 through 20, please refer to [Full Text View] on ClinicalTrials.gov. (For question 3, 
please also refer to [Tabular View]).  
 
2. Look at the ‘Study Design’ section of the [Full text view]. Is “Crossover Assignment” selected for 
“Intervention Model’? 
[Full Text View]  [Purpose] [Study Design] 
(   1) Yes  
(    2) No (Stop and inform Lijuan Zeng: lzeng3@jhu.edu) 
 
3. Look at the ‘Purpose’, ‘Detailed Description’ (if available) and ‘Arms’ sections of the [Full Text 
View], as well as the ‘Brief Summary’ and the ‘Detailed Description’ of the [Tabular View]. In your 
opinion, does this registration describe a phase 3 randomized crossover trial? 
[Full Text View]  [Purpose]  [Detailed Description] (Note: some studies may not have ‘detailed 
description’ next to the ‘Arms’ table)  
(   1) Yes (Skip to 5)  
(   2) No (Continue to 4)   
(   3) Cannot tell (Stop and inform Lijuan Zeng: lzeng3@jhu.edu) 
Randomized crossover trial: a clinical trial in which groups of participants are randomized to receive 
two or more interventions in a particular order. 
 
4. Why do you think this is not a phase 3 randomized crossover trial? 
(   1) The ‘crossover’ is not randomized (see example below).  
(   2) The study had multi-phases (e.g., phases 2 and 3) and the ‘crossover’ is not in phase 3.  
(   3) Cannot tell (Stop and inform Lijuan Zeng: lzeng3@jhu.edu) 
(Example: If the crossover is described as “participants were offered the option to cross over to X 
treatment”, the crossover in the trial was not randomized.) 
 
ID: NCT__ __ __ __ __ __ __ __  
Purpose:  
This form is designed for assessing the study design, analysis and reporting of phase 3 
crossover trials registered on ClinicalTrials.gov. 
 
Instruction: 
- Italic text section provides instructions for how each question. Use the tree-structure 
instruction after each question to help you locate the data fields.  
[Section]  [Sub-section]  [Sub-Subsection] 
- * mark before each question indicates that data for this question can be extracted directly 
from ClinicalTrials.gov, and will not need to extract on electronic form. 
      
Completed by whom: 








5. Based on ‘Purpose’ and/or ‘Detailed Description’ (if available), is a washout period included in this 
trial? (A washout period can be described in text, or reported in a tabular format) 
(   1) Yes. 
(   2) No. 
(   3) Cannot tell. 
The washout period is the interval of time considered necessary for a biological system to remove a 
foreign substance and to be free of its influence. 
 
*6. What is the registered ‘Endpoint classification/Study Classification’? 
[Full Text View]  [Purpose]  [Study Design]  [Endpoint Classification/Study Classification] 
(   1) Not reported 
(   2) Safety Study 
(   3) Efficacy Study 
(   4) Safety/Efficacy Study 
(   5) Bio-equivalence Study 
(   6) Bio-availability Study 
(   7) Pharmacokinetics Study 
(   8) Pharmacodynamics Study 
(   9) Pharmacokinetics/dynamics Study 
(   10) Others, please specify, a: _____________________________________________________ 
 
*7. What is the registered ‘Primary Purpose’ under the ‘Study Design’? 
[Full Text View]  [Purpose]  [Study Design]  [Primary Purpose] 
(   1) Treatment 
(   2) Prevention 
(   3) Diagnostic  
 
*8. How is ‘Masking’ registered?  
[Full Text View]  [Purpose]  [Study Design]  [Masking] 
(   1) Open-label (Skip to 10) 
(   2) Single blind  
(   3) Double blind  
 
*9. Based on the registration, which of the following parties are masked in the ‘single-blind’ or 
‘double-blind’ design? (Check all that apply) 
[Full Text View]  [Purpose]  [Study Design]  [Masking] 
Yes     No 
(   1)   (   2) a. Subject 
(   1)   (   2) b. Caregiver 
(   1)   (   2) c. Investigator 
(   1)   (   2) d. Outcomes Assessor 
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*10. What are the registered the ‘Intervention’ types under ‘Intervention’? (Check all that apply) 
[Full Text View]  [Purpose]  [Intervention] 
Yes     No 
(   1)   (   2) a. Drug 
(   1)   (   2) b. Device 
(   1)   (   2) c. Biological/Vaccine 
(   1)   (   2) d. Procedure/Surgery 
(   1)   (   2) e. Behavioral  
(   1)   (   2) f. Dietary Supplement 
(   1)   (   2) g. Other. Please specify: h:_______________________________________________ 
 
For question 11 to 13, please refer to the ‘Arms’, ‘Assigned interventions’ and ‘Intervention’ cells of 
the [Full Text View].  
[Full Text View]  [Purpose]  [Arms], [Assigned Interventions] & [Intervention] 
 
11. Based on the information presented in these cells, in your opinion, how many interventions are 
compared in the trial? (Indicate the number of interventions compared in the crossover phase, 
excluding interventions used only in the run-in period, washout period, run-out period, and standard 
of care given to participants for the entire study period) 
(   1) 2 
(   2) 3 
(   3) 4 
(   4) 5 
(   5) 6 
(   6) > 6, please specify the number of compared interventions, a: _________________________ 
(   7) Cannot tell 
(Please refer to examples in the Appendix 3) 
 
12. How many treatment periods are registered? (Indicate the number of periods in which 
interventions are compared, excluding run-in periods, washout periods, and run-out periods) 
(   1) 2 
(   2) 3 
(   3) 4 
(   4) 5 
(   5) 6 
(   6) > 6. Please specify the number of periods, a: ______________________________________ 
(   7) Cannot tell 
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13. How many sequences are registered? (Indicate the number of periods in which interventions are 
compared, excluding run-in periods, washout periods, and run-out periods) 
(   1) 2 
(   2) 3 
(   3) 4 
(   4) 5 
(   5) 6 
(   6) > 6. Please specify the number of compared interventions, a: _________________________ 
(   7) Cannot tell 
 
14. What are the registered sequences? 
(   1) AB|BA 
(   2) ABAB|BABA  
(   3) ABA|BAB 
(   4) ABC|ACB|BAC|BCA|CBA|CAB 
(   5) Other sequence design. Please specify, a: ________________________________________ 
______________________________________________________________________________ 
e.g.:  AB|BA; ABC|BCA|CBA; ABAB|BABA; ABC|ACB|BCA|BAC|CAB|CBA etc.  
(Use different alphabetic letters for different interventions; separate sequences with ‘|’)  
 
15. How are the ‘Arms’ registered? (Check all that apply) 
[Full Text View]  [Purpose]  [Arms] 
Yes     No 
(   1)   (   2) a. By Sequence 
(   1)   (   2) b. By Intervention 
(   1)   (   2) c. By Period 
(   1)   (   2) d. Others. Please specify. f: _______________________________________________ 
(   1)   (   2) e. Cannot tell 
(Please refer to examples in the Appendix 3) 
 
*16. Please copy and paste the information provided in the ‘Arm’ column into the textbox below (one 
row for one arm): 
 
17. Based on questions 15 and 16, in your opinion, does the trial registration of the ‘Arms’ account 
for the crossover design? 
(   1) Yes. 
(   2) No. Please specify why, a: ____________________________________________________ 








ID: NCT__ __ __ __ __ __ __ __  
 
 




18. How is the information in ‘Assigned Interventions’ columns presented?  
[Full Text View]  [Purpose]  [Assigned Interventions] 
(   1) Treatment details in ‘Assigned interventions’ cells are the same for all rows. 
(   2) Treatment details in ‘Assigned interventions’ cells are not the same for all rows. 
(   3) Others. Please specify. a: _____________________________________________________ 
(Please refer to examples in the Appendix 3) 
 
*19. Please copy and paste the information provided in the ‘Assigned intervention’ column into the 
textbox below (one row for one arm): 
 
20. Based on questions 18 and 19, in your opinion, does the trial registration of the ‘Assigned 
Interventions’ account for the crossover design? 
(   1) Yes. 
(   2) No. Please specify why, a: ____________________________________________________ 
(   3) Cannot tell. Please specify why, b:______________________________________________ 
 
 
From questions 21 through 41, please refer to [Study Results] tab on ClinicalTrials.gov. 
 
Questions 21-24 refer to the ‘Participant Flow’ section of the [Study Results] 
 
21. Look at the ‘Participant Flow’ table. In your opinion, how many treatment periods are registered? 
(Indicate the number of periods in which interventions are compared, excluding run-in periods, 
washout periods, and run-out periods.) 
(   1) 2 
(   2) 3 
(   3) 4 
(   4) 5 
(   5) 6 
(   6) > 6. Please specify the number of periods, a: ______________________________________ 


















22. How are the ‘Reporting Groups’ presented? (Check all that apply) 
[Study Results]  [Participant Flow]  [Reporting Groups] 
Yes     No 
(   1)   (   2) a. By Sequence 
(   1)   (   2) b. By Intervention 
(   1)   (   2) c. By Period 
(   1)   (   2) d. Others. Please specify, f: _______________________________________________ 
(   1)   (   2) e. Cannot tell 
(Please refer to examples in the Appendix 3) 
 
23. How are the ‘Participant Flow’ tables presented?  
(   1) One table only for Overall Study / Total population / All participants. 
(   2) Separate tables by Period, without pre-randomization and/or washout periods 
(   3) Separate tables by Period, with pre-randomization and/or washout periods  
(   4) Others. Please specify, a: _____________________________________________________  
(   5) Cannot tell 
(Please refer to examples in the Appendix 3) 
 
24. Based on questions 21 to 23, in your opinion, does the registration of the ‘Participant Flow’ 
account for the crossover design? 
(   1) Yes. 
(   2) No. Please specify why, a: ____________________________________________________ 
(   3) Cannot tell. Please specify why, b:______________________________________________ 
 
For question 25, please refer to the ‘Baseline Characteristics’ section of the [Study Results]. 
25. How are the ‘Reporting Groups’ presented? (Check all that apply) 
[Study Results]  [Baseline Characteristics]  [Reporting Groups] 
Yes     No 
(   1)   (   2) a. By Total  
(   1)   (   2) b. By Sequence 
(   1)   (   2) c. By Intervention  
(   1)   (   2) d. By Period  
(   1)   (   2) e. Others. Please specify, f: _______________________________________________ 
 
For question 26, please refer to the ‘Outcome Measures’ section of the [Study Results] 
26. How many primary outcomes are registered? 
(   1) 1 
(   2) 2 
(   3) 3 









ID: NCT__ __ __ __ __ __ __ __  
 
 




For question 27 to 41, please refer to the first listed primary outcome of [Study Results] page. 
[Study Results]  [Outcome Measures]  [1. Primary: …]  
 
27. What is the title of the 1st primary outcome?  
(Please copy and paste the description in the ‘Measure Title’ under ‘1. Primary’) 
 
(Please refer to examples in the Appendix 3) 
 
28. In your opinion, what is the outcome type for the 1st primary outcome? 
(   1) Continuous outcome (Skip to 30) 
(   2) Categorical outcome (Skip to 30) 
(   3) Time-to-event outcome (Continue to 29) 
(   4) Others. Please specify: a: ___________________________________________ (Skip to 30)  
(   5) Cannot Tell. (Skip to 30) 
 
29. For Time-to-Event outcome, how is the outcome registered?  
(   ) Reported as continuous data (e.g.: mean time to event with measure of dispersion) 
(   ) Reported as categorical data at different time points by arm or comparison group 
 
30. After looking at ‘Measure Title’, ‘Measure Description’ and ‘Measured Values’, what is the 
specific metric for the 1st primary outcome? 
(   1) Value at a time-point  
(   2) Time-to-event 
(   3) Change from the baseline before randomization 
(   4) Change from the period-baseline (i.e.: change from baseline of period 2) 
(   5) Within-individual difference between values at the end of each period 
(   6) Within-individual difference between changes from baseline 
(   7) Within-individual indicator of concordant versus discordant events between periods 
(   8) Others. Please specify, a: _____________________________________________________  
(   9) Cannot tell 
The ‘specific metric’ is the format of the outcome data from each participant that is used for analysis 
 
31. Based on the ‘Measured Values’, what is the method of aggregation for the 1st primary outcome?  
(   1) Number 
(   2) Mean 
(   3) Median 
(   4) Least Squares Mean 
(   5) Geometric Means 
(   6) Log Mean 
(   7) Proportion/percent 
(   8) Others. Please specify, a: _____________________________________________________  
(   9) Cannot tell  
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32. Based on the ‘Time Frame’ information, in your opinion, does the ‘Time Frame’ for the 1st 
primary outcome includes all randomized periods?  
[Study Results]  [Outcome Measures]  [1. Primary: …]  [Time Frame]  
(   1) Yes. 
(   2) No. Please specify why, a: ____________________________________________________ 
(   3) Cannot tell. Please specify why, b:______________________________________________ 
 
33. Based on the ‘Time Frame’ information, in your opinion, data from which periods are used for 
analyzing the primary outcome? 
(   1) Data from all periods 
(   2) Data from first period only 
(   3) Data from more than one period but not all periods 
(   4) Others. Please specify, a: _____________________________________________________  
(   5) Cannot tell 
 
34. Based on questions 27 to 33, is the definition for the 1st primary outcome appropriate for the 
crossover design?  
(   1) Yes. 
(   2) No. Please specify why, a: ____________________________________________________ 
(   3) Cannot tell. Please specify why, b:______________________________________________ 
(Please refer to examples in the Appendix 3) 
 
35. What is the registered ‘Analysis Population’? (Described in the ‘Population Description’) 
(Check all that apply) 
Yes     No 
(   1)   (   2) a. ITT (Intention-To-Treat) 
(   1)   (   2) b. Per-protocol  
(   1)   (   2) c. As treated 
(   1)   (   2) d. mITT (modified Intention-To-Treat) 
(   1)   (   2) e. FAS (Full Analysis Set) 
(   1)   (   2) f. Others. Please specify, h: _______________________________________________ 
(   1)   (   2) g. Not reported (Skip to 37) 
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37. How are the ‘Reporting Groups’ presented? (Check all that apply) 
[Study Results]  [Outcome Measures]  [1. Primary: …]  [Reporting Groups]  
Yes     No 
(   1)   (   2) a. By Total  
(   1)   (   2) b. By Sequence 
(   1)   (   2) c. By Intervention  
(   1)   (   2) d. By Period  
(   1)   (   2) e. Others. Please specify, f: _______________________________________________ 
 
38. Based on the ‘Measured Values’, are the results presented by period? 
[Study Results]  [Outcome Measures]  [1. Primary: …]  [Measured Values]  
(   1) Yes. 
(   2) No.  
(   3) Cannot tell. Please specify, a:__________________________________________________ 
(Please refer to examples in the Appendix 3) 
 
39. Is a description of the ‘Statistical analysis’ provided after the ‘Measured Values’ section? 
(   1) Yes (Continue to 40) 
(   2) No (Skip to 41) 
(   3) Cannot tell 
(Please refer to examples in the Appendix 3) 
 
*40. Based on ‘Method’ information in ‘Statistical Analysis’, what is/are the registered statistical 
method(s) for estimation? (Check all that apply) 
Yes     No   
(   1)   (   2) a. ANCOVA 
(   1)   (   2) b. ANOVA 
(   1)   (   2) c. Chi-squared test 
(   1)   (   2) d. Chi-squared test, Corrected 
(   1)   (   2) e. Cochran-Mantel-Haenszel 
(   1)   (   2) f. Fisher Exact 
(   1)   (   2) g. Kruskal-Wallis 
(   1)   (   2) h. Log Rank 
(   1)   (   2) i. Mantel Haenszel 
(   1)   (   2) j. McNemar 
(   1)   (   2) l. Mixed Models Analysis 
(   1)   (   2) m. Regression, Cox 
(   1)   (   2) n. Regression, Linear 
(   1)   (   2) o. Regression, Logistic 
(   1)   (   2) p. Sign test 
(   1)   (   2) q. t-test, 1 sided 
(   1)   (   2) r. t-test, 2 sided 
(   1)   (   2) u. Wilcoxon (Mann-Whitney) 
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41. Based on questions from 27 to 40, in your opinion, does the registration of the results of the 1st 
primary outcome account for the crossover design? 
(   1) Yes.  
(   2) No. Please specify why, a: ____________________________________________________ 




For questions 42 and 43, please refer to ‘Serious Adverse Events’ and/or ‘Other Adverse Events’ 
sections.  
 
42. Are there any adverse events registered? 
(   1) Yes.  
(   2) No. (Skip to 44) 
(   3) Cannot tell 
 
43. How are the adverse events ‘Reporting Groups’ presented? (Check all that apply) 
[Study Results]  [Serious Adverse Events] or [Other Adverse Events] 
Yes     No 
(   1)   (   2) a. By Total  
(   1)   (   2) b. By Sequence 
(   1)   (   2) c. By Intervention  
(   1)   (   2) d. By Period  
(   1)   (   2) e. Others. Please specify, f: _______________________________________________ 
 
 
Review of the entire registration 







45. Form Completed Date (MM/DD/YYYY): __ __ / __ __ / __ __ __ __ 
 
46. Initials of the data abstractor: __ __ 
 
47. Name of the data abstractor: _______________________  __________________________ 
                  First          Last 
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Appendix 3. Examples for using ‘Data Abstraction Form for Crossover Trials’ 
 
 
Example for question 11: How many interventions are compared in the trial? 
Example 1:  




Example 2:  
In this study (NCT00004635), although 4 interventions were involved, only Thalidomide and Placebo 
interventions were compared to one another. (After reading ‘Arms’ section about study design, we 
learned that the other 2 drugs were used during run-in or washout periods only). Therefore, we count 
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Example for question 12: How many treatment periods are registered?  
Example: 





Example for question 15: How are the ‘Arms’ registered? 
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Example for question 18: How is the information in ‘Assigned Interventions’ columns presented? 
Example 1: Option 1. Treatment details in ‘Assigned interventions’ cells are the same for all rows. 
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Example for question 22: How are the ‘Reporting Groups’ presented? 
Example: The trial (NCT00127166) specifies that the ‘Reporting Groups’ in ‘Participant Flow’ 
section in ‘by sequence’ format, the column names for ‘Participant Flow’ table will be labeled 







Example for question 23: How are the ‘Participant Flow’ tables presented?  
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Example 2: Trial (NCT00432744) presents separate tables by Period, without pre-randomization 
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Example for question 34: Is the definition for the 1st primary outcome appropriate for the crossover 
design? 
Example 1: The definition for the 1st primary outcome is appropriate for the crossover design. 
The 1st primary outcome in the trial (NCT00432744) is a continuous outcome, GMFM 88. The 
treatment effect is estimated using within-subject differences between values at the end of period 1 (6 
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Example 2: The definition for the 1st primary outcome is not appropriate for the crossover design. 
The 1st primary outcome in the trial (NCT 00364182) is analyzed as a continuous outcome. The 
treatment effect is estimated by comparing baseline (On-demand) level to the average of those 
receiving from both randomization period 1 and period 2, or comparing pooled data from both 
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Example for question 38: 
Example:  




Example for question 39: 
Example 1: With Statistical analysis 
 















Appendix 4. Illustration of registering ‘Arms/Interventions’ on ClincialTrials.gov 
system 
When registering ‘Arms’ information on ClinicalTrials.gov system, registrars are required to 
provide at least ‘Arm Label’ and ‘Arm Type’ information in order to register a certain arm. 
Additionally, there is an optional cell for ‘Arm Description’ for each arm section. An 
illustrative example of registering ‘Arms’ details on registration system was shown in Figure 
17. 
  
Figure 17. Illustration for registering ‘Arms’ details on ClinicalTrials.gov system 
  
 
Then registrars register all interventions involved in the trial in a separate page in a format 
shown in Figure 18. Finally, assigned interventions are identified by checking the cross-




interventions would be listed in ‘Assigned Interventions’ columns corresponding to each 
specified arm. 
 
Figure 18. Illustration of registering ‘Interventions’ on ClinicalTrials.gov system 
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